Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT-HGG-2013: Valproic Acid in Pediatric High Grade Glioma
NCT03243461Phase 3Unknown
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Jul 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of valproic acid in high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), gliomatosis cerebri (GC) and 2 more, sponsored by Georg-August-Universität Göttingen. Primary endpoint: Event-free survival at 5.4 years. Status: unknown.
02
Drugs
valproic acid
03
Conditions
high-grade glioma (HGG)diffuse intrinsic pontine glioma (DIPG)gliomatosis cerebri (GC)anaplastic astrocytoma (AA)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03243461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243461.